文献速递抗栓抗凝管理药物不良反应与药物警戒

低剂量与高剂量四因子凝血酶原复合物在Xa因子抑制剂相关出血中的效果:定性系统评价

Effect of low- versus high-dose 4-factor prothrombin complex concentrate in factor Xa inhibitor-associated bleeding: A qualitative systematic review.
PubMed 文献 · Am J Health Syst Pharm · 2024-01-01

本综述旨在评估四因子凝血酶原复合物(4F-PCC)治疗Xa因子抑制剂相关出血的文献,重点比较低剂量与高剂量4F-PCC对止血效果和安全性的影响。检索PubMed和EBSCOhost后纳入4项研究,结果显示低剂量与高剂量队列的止血有效率、院内死亡率和静脉血栓栓塞发生率相似。结论提示低剂量与高剂量4F-PCC可能具有相似的临床有效性和安全性,但需前瞻性研究进一步证实。

要点

  • 低剂量与高剂量4F-PCC在Xa因子抑制剂相关出血中止血效果相似。
  • 两种剂量方案的院内死亡率和静脉血栓栓塞发生率未见明显差异。
  • 现有证据有限,需前瞻性研究确认剂量选择。

核心结论

  • 低剂量与高剂量4F-PCC可能提供相似的临床有效性和安全性。

研究设计与样本

  • 定性系统评价,检索PubMed和EBSCOhost,纳入4项评估Xa因子抑制剂相关出血患者使用低或高剂量4F-PCC的研究。

主要发现

  • 在每项纳入研究中,低剂量和高剂量队列的止血有效率、院内死亡率和静脉血栓栓塞发生率相似。

临床怎么用

  • 临床可考虑低剂量4F-PCC用于Xa因子抑制剂相关出血,但需结合个体情况并关注后续证据。

局限性

  • 结论需前瞻性研究进一步评估和确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this review is to evaluate current literature on the treatment of factor Xa inhibitor-associated bleeds with 4-factor prothrombin complex concentrate (4F-PCC), with a focus on the effect of low versus high dosing of 4F-PCC on hemostatic efficacy and safety outcomes. SUMMARY: A search of PubMed and EBSCOhost was performed to identify studies evaluating patients with a factor Xa inhibitor-bleed treated with 4F-PCC at either low or high doses. Studies of patients receiving alternative reversal agents such as fresh frozen plasma and andexanet alfa or where no comparator group was evaluated were excluded from the analysis. To assess the effect of these 4F-PCC dosing strategies, the primary outcome of interest was hemostatic efficacy. Four studies meeting inclusion criteria were included in this review. In each of the included studies, similar rates of hemostatic efficacy, hospital mortality, and venous thromboembolism were observed in the low- and high-dose cohorts. CONCLUSION: These results suggest low- and high-dose 4F-PCC may confer similar clinical effectiveness and safety; however, these findings should be evaluated and confirmed with future prospective studies.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Phillips A, Bradley C, Cash J, et al. Effect of low- versus high-dose 4-factor prothrombin complex concentrate in factor Xa inhibitor-associated bleeding: A qualitative systematic review. Am J Health Syst Pharm. 2024. PMID: 38430127. doi:10.1093/ajhp/zxae009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。